Solgene Therapeutics LLC
This article was originally published in Start Up
Executive Summary
[Solgene Therapeutics LLC] has developed a method of encapsulating living cells that secrete therapeutic compounds into porous ceramic microbeads. Solgene's approach is designed to mimic the way cells are released in nature: in consistent and low doses over a sustained period of time, without triggering an immune reaction. It believes that its technology will prove an effective means of delivering a variety of large molecule compounds.
You may also be interested in...
Drug Delivery Start-Ups
As an industry segment, drug delivery was virtually created by two companies--Alza Corp. and Elan Corp. PLC. These companies have since evolved into drug companies, abandoning a significant part of the field to second-generation arrivistes. Such companies that have survived the funding drought for small-cap companies have benefited, Inhale Therapeutics, for example, has a number of partnerships for its pulmonary delivery technology. Alkermes, probably the leading drug-delivery pure play, now has its first approved product. What is somewhat surprising about the industry is how little it has consolidated, particularly when one considers that no single drug delivery technology is applicable to a majority of drug delivery problems.
In Vivo's Deals Of The Month, February 2018
In Vivo's editors pick January's most significant deals, including Roche's acquisition of Flatiron and Moderna's latest big private fundraising. (Free article.)
In Vivo's Deals Of The Month, January 2018
In Vivo's editors pick January's most significant deals, including an alliance of players new to health care and Celgene's big buys. (Free article.)